Department of Pharmacy, Hospital Universitari del Mar, Barcelona, Spain.
IMIM (Instituto de Investigación Hospital del Mar), Barcelona, Spain.
J Chemother. 2021 Feb;33(1):32-39. doi: 10.1080/1120009X.2020.1849488. Epub 2020 Dec 3.
Our aim was to describe the incidence and characteristics of immune-related adverse events (irAEs) in patients with non-small-cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and to evaluate their impact on outcome. All cases of NSCLC patients treated with ICIs in the second-line setting between December 2015 and May 2018 were evaluated. Seventy patients were included. Mean age was 65.9 years, and the majority of male ( = 53, 75.7%), with PS of 0-1 ( = 62, 88.6%) treated with nivolumab ( = 51; 72.9%). Thirty-one patients (44.3%) experienced an AE, 5 (7.1%) were grades 3-4. Median OS in patients with AE was 30.1 months (95% CI, 16.7-43.5) compared with 5.1 months (95% CI, 1.2-9.0) in cases without AE (log-rank test: = 0.010). The adjusted HR for OS was 0.46 (95% CI, 0.25-0.86) for the irAE occurrence and 3.60 (95% CI, 1.56-8.32) for PS 2-3 group. The development of irAEs was associated with improved patient outcome.
我们的目的是描述接受免疫检查点抑制剂（ICI）治疗的非小细胞肺癌（NSCLC）患者发生免疫相关不良事件（irAE）的发生率和特征，并评估其对结局的影响。评估了 2015 年 12 月至 2018 年 5 月间二线接受 ICI 治疗的 NSCLC 患者的所有病例。共纳入 70 例患者。平均年龄为 65.9 岁，大多数为男性（n=53，75.7%），PS 0-1（n=62，88.6%），接受纳武单抗（n=51；72.9%）治疗。31 例（44.3%）患者发生 AE，5 例（7.1%）为 3-4 级。有 AE 的患者的中位 OS 为 30.1 个月（95%CI，16.7-43.5），而无 AE 的患者为 5.1 个月（95%CI，1.2-9.0）（对数秩检验：P=0.010）。AE 发生的 OS 调整 HR 为 0.46（95%CI，0.25-0.86），PS 2-3 组为 3.60（95%CI，1.56-8.32）。irAE 的发生与患者结局的改善相关。
